- Home
- VXRT
VXRT
Vaxart Inc
as 05-30-2025 4:00pm EST
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 119.0M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $1.07 | Next Earning Date: | 05-13-2025 |
| Revenue: | $47,395,000 | Revenue Growth: | 433.43% |
| Revenue Growth (this year): | -81.87% | Revenue Growth (next year): | -24.51% |
Latest Vaxart Inc News
VXRT Breaking Stock News: Dive into VXRT Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
GlobeNewswire
3 days ago
Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders
GlobeNewswire
4 days ago
Vaxart Answers Additional Frequently Asked Questions from Retail Investors
GlobeNewswire
5 days ago
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
11 days ago
Vaxart Announces Adjournment of Annual Meeting of Stockholders
GlobeNewswire
12 days ago
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
16 days ago
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting
GlobeNewswire
17 days ago
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
Compare VXRT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VXRT Vaxart Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.